Alebund Pharmaceuticals says no market purchases made for price stabilization during IPO stabilisation period

• Alebund Pharmaceuticals (Jiangsu) fully exercised its over-allotment option on July 24, 2026 for 8,513,300 H shares at HK$ 22.6.
• The issue covered 8,513,300 H shares of international offering over-allocations, equal to about 15% of offer shares pre-greenshoe.
• The stabilization period ended July 24, 2026; Jefferies Hong Kong ran stabilization with no on-market stabilizing trades.
• Additional net proceeds from the over-allotment shares totaled about HK$ 184.7 million, earmarked pro rata to stated IPO uses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alebund Pharmaceuticals (Jiangsu) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260724-12255129), on July 24, 2026, and is solely responsible for the information contained therein.